Neo-Mercazole Carbimazole

Neo-Mercazole is a well-established pharmaceutical product used primarily for the treatment of hyperthyroidism. The active ingredient, carbimazole, acts as a pro-drug that is converted to methimazole in the body to manage thyroid hormone levels. Originally developed and marketed by various legacy pharmaceutical firms, the brand has undergone several ownership transitions as the global pharmaceutical landscape consolidated.

Today, the brand is owned by Advanz Pharma (formerly known as Concordia International), which acquired it through its subsidiary Amdipharm. Amdipharm was a key player in managing 'legacy' medicines before its merger and eventual integration into the Advanz Pharma portfolio. Manufacturing occurs in multiple certified pharmaceutical facilities globally to serve different regional markets, with a significant presence in European and Asian healthcare systems.

Advanz Pharma is headquartered in London, United Kingdom, and specializes in complex medicines and critical care therapies. The company operates as a global pharmaceutical entity, ensuring that essential treatments like Neo-Mercazole remain available to patients long after their initial patent expiration.